NCT06702943View on ClinicalTrials.gov

Comparing Tigecycline Vs. Colistimethate in CNS Infections

Not yet recruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

June 30, 2027

Conditions
Central Nervous System Infections
Interventions
DRUG

Tigecycline (Tygacil)

tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days

DRUG

Colistimethate sodium (CMS)

Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06702943 - Comparing Tigecycline Vs. Colistimethate in CNS Infections | Biotech Hunter | Biotech Hunter